Rua Life Sciences PLC
LSE:RUA

Watchlist Manager
Rua Life Sciences PLC Logo
Rua Life Sciences PLC
LSE:RUA
Watchlist
Price: 12.4 GBX -0.8% Market Closed
Market Cap: 7.7m GBX
Have any thoughts about
Rua Life Sciences PLC?
Write Note

Net Margin
Rua Life Sciences PLC

-65.7%
Current
-102%
Average
2.1%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-65.7%
=
Net Income
-1.4m
/
Revenue
2.2m

Net Margin Across Competitors

Country UK
Market Cap 7.7m GBP
Net Margin
-66%
Country JP
Market Cap 7T JPY
Net Margin
24%
Country CH
Market Cap 37.9B CHF
Net Margin
12%
Country DK
Market Cap 178.7B DKK
Net Margin
19%
Country US
Market Cap 16.1B USD
Net Margin
11%
Country KR
Market Cap 10.3T KRW
Net Margin
-358%
Country CN
Market Cap 49B CNY
Net Margin
42%
Country US
Market Cap 6.5B USD
Net Margin
29%
Country CA
Market Cap 6.4B USD
Net Margin
-8%
Country UK
Market Cap 4.6B GBP
Net Margin
7%
Country US
Market Cap 5.7B USD
Net Margin
9%
No Stocks Found

Rua Life Sciences PLC
Glance View

Market Cap
7.7m GBX
Industry
Health Care

RUA Life Sciences Plc is a holding company, which engages in the commercialization of biomedical polymer technology, components, and medical devices. The company is headquartered in Ayrshire, Ayrshire and currently employs 32 full-time employees. The firm is a manufacturer of medical devices and licensor of its IP and know-how together with developing medical devices utilizing its polymer IP. The firm operates through four businesses. Its RUA Medical business provides sub-contract manufacturing, assembly, packing and services to the medical device sector from its Class seven and eight cleanroom suites. Its RUA Biomaterials is the depository of the IP and licensing rights to a range of biostable, implantable polymers, including Elast-EonTM and ECSilTM. Its RUA Vascular business is the legal manufacturer and IP holder of the Company’s cardiovascular and soft tissue patches and bore vascular grafts. Its RUA Structural Heart business holds the intellectual property relating to the Company’s synthetic heart valve technology.

RUA Intrinsic Value
10.35 GBX
Overvaluation 17%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-65.7%
=
Net Income
-1.4m
/
Revenue
2.2m
What is the Net Margin of Rua Life Sciences PLC?

Based on Rua Life Sciences PLC's most recent financial statements, the company has Net Margin of -65.7%.